EN DE
Watch Kolon Life Science Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kolon Life Science Inc (102940) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Kolon Life Science Inc stock KRW 37,195, price KRW 12,450, upside +198.8%, quality 35 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7102940004

KL Kolon Life Science Inc logo Some data Nov 6, 2026

Kolon Life Science Inc

102940 · KQ
Cheap, value-trap risk

The stock costs 67% less than our calculation considers fair.

Fair value 37,195 KRW · Strongly undervalued
Solidly profitable · 11.9% net margin (FY2025)
Low debt
Ranks above peers (6/10)
Even on cautious assumptions the value is 112% above the price (26,432 KRW).
Expensive Growth (revenue 5y +10.1 %/yr in KRW)
Some data
Quality 35/100
Negative free cash flow
Narrow moat 34/100 · thin data
Watch Kolon Life Science Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

70,800 KRW 12,380 KRW Fair Value 37,195 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range 12,380 KRW – 70,800 KRW · fair‑value band 26,432 KRW – 46,493 KRW · the 12,450 KRW price screens below the 37,195 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Kolon Life Science in your weekly email

Every Wednesday you see whether Kolon Life Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea.

Show moreShow less

Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain.

The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters.

In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants.

The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Stock analysis

Kolon Life Science Inc (102940) currently trades at 12,450 KRW, while our model-based Fair Value estimate is 37,195 KRW, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 37,760 KRW per share, and 11 of the 14 models we run sit above the 12,450 KRW price.

Bear case: the Economic Profit group reads lowest at 20,335 KRW, and 3 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 26,432 KRW (bear) to 46,493 KRW (bull), the price of 12,450 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Kolon Life Science Inc reported revenue of 209B KRW in FY2025 versus 165B KRW in FY2021, a compound +6.0%/yr. Reported net income was 25.0B KRW in FY2025.

Key figures

Market cap 169B KRW (≈ $125M) Micro · P/S ratio 0.89 · Net margin −3.0% · Return on equity −3,386% · Return on assets (EBIT) −4.3% (5-year average) · Operating margin 0.7% · Revenue (TTM) 191B KRW · Revenue growth (YoY) +20.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades about 82% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 199%, 102940 screens cheaper than that median.

Fair Value models

Bear 26,432 KRW Fair Value 37,195 KRW Bull 46,493 KRW
Price 12,450 KRW · Upside +198.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 8,246 KRW 9,103 KRW 9,788 KRW 74
ROIC Compounder 8,246 KRW 9,103 KRW 9,788 KRW 72
Residual Income 31,507 KRW 31,567 KRW 33,451 KRW 71
All 14 models by family
Earnings-Based
Graham-Dodd 14,878 KRW 58,574 KRW 79,527 KRW 64
Lynch FV 14,458 KRW 20,654 KRW 26,850 KRW 61
PEG = 1.0 14,458 KRW 20,654 KRW 26,850 KRW 57
EPV 8,246 KRW 9,103 KRW 9,788 KRW 74
Multiples
P/E Multiple 36,101 KRW 48,134 KRW 60,168 KRW 63
P/S Multiple 27,896 KRW 37,195 KRW 46,493 KRW 58
P/B Multiple 78,212 KRW 104,282 KRW 130,353 KRW 55
EV/EBIT 8,526 KRW 14,041 KRW 19,557 KRW 64
EV/EBITDA 14,591 KRW 22,129 KRW 29,666 KRW 66
EV/Revenue 3,789 KRW 8,850 KRW 13,911 KRW 50
Asset-Based
NCAV (Graham) 25,552 KRW 34,240 KRW 51,104 KRW 54
Economic Profit
Residual Income 31,507 KRW 31,567 KRW 33,451 KRW 71
ROIC Compounder 8,246 KRW 9,103 KRW 9,788 KRW 72
Growth Earnings
Growth-Adj P/E 26,432 KRW 37,760 KRW 49,088 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 3
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+29.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−20.9% (2020) → 7.1% (2025)

Watch 102940, get fair value alerts →

Compare Kolon Life Science Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside +196.4% · Top 25%
Profitability
Return on assets 2.7% · Below median
Net margin (12 months) 11.9% · Top 25%
Operating margin (12 months) 0.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 20.2% · Above median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 0.29× · Cheapest 25%
P/S (12 months) 0.89× · Cheaper than median
EV/EBITDA 14.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 14
FUTURE (revenue growth)100 · sector 51
PAST (return on equity)0 · sector 15
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 18,800 KRW 47,019 KRW +150% vs 102940
DongKook Pharmaceutical Co 086450 23,550 KRW 28,372 KRW +20% vs 102940
VIKRAMTH VIKRAMTH ₹319.35 ₹351.29 +10% vs 102940
ST Pharm Co 237690 72,600 KRW 61,182 KRW −16% vs 102940
EURO EURO 1.26 PHP 0.8000 PHP −37% vs 102940
Oscotec Inc 039200 36,300 KRW 21,262 KRW −41% vs 102940
BINEX Co 053030 5,910 KRW 1,844 KRW −69% vs 102940
ISU Abxis Co 086890 3,200 KRW 727.12 KRW −77% vs 102940
Caregen Co 214370 28,150 KRW 5,414 KRW −81% vs 102940
SHUKRAPHAR SHUKRAPHAR ₹79.97 ₹9.14 −89% vs 102940

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kolon Life Science Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kolon Life Science Inc Fair Value". https://www.fairvalue-calculator.com/stock/102940

Frequently asked questions

Is Kolon Life Science Inc (102940) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 37,195 KRW versus a price of 12,450 KRW, about +199% upside (undervalued).
What is the fair value of 102940?
Our model-based fair value for Kolon Life Science Inc is 37,195 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 12,450 KRW.
What is the quality score of 102940?
Kolon Life Science Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kolon Life Science Inc (102940)?
Our model-based price target is the fair value of 37,195 KRW (as of Nov 6, 2026) from 14 valuation models. Cautious scenario 26,432 KRW, optimistic scenario 46,493 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kolon Life Science Inc stock forecast for 2026?
Our models put fair value at 37,195 KRW, about +199% upside versus a price of 12,450 KRW (undervalued). Cautious scenario 26,432 KRW, optimistic scenario 46,493 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kolon Life Science Inc (102940)?
Kolon Life Science Inc reported trailing-twelve-month revenue of about 191B KRW (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Kolon Life Science Inc (102940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kolon Life Science Inc it is 37,195 KRW per share (as of Nov 6, 2026), against a price of 12,450 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Kolon Life Science Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 102940 trades below its calculated fair value: price 12,450 KRW, fair value 37,195 KRW, a gap of about +199% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 102940?
No. The price is what the market pays today (12,450 KRW); the fair value is what the company's own numbers justify (37,195 KRW). For Kolon Life Science Inc the two are 24,745 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kolon Life Science Inc worth?
The market values Kolon Life Science Inc at about 169B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 12,450 KRW; our models calculate a fair value of 37,195 KRW per share.
What do the bullish and bearish scenarios say about 102940?
Our models span a range for Kolon Life Science Inc: cautious scenario 26,432 KRW, base 37,195 KRW, optimistic 46,493 KRW per share (as of Nov 6, 2026, price 12,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kolon Life Science Inc (102940)?
Balance-sheet figures for Kolon Life Science Inc (as of Nov 6, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 102940 from its 52-week high?
Kolon Life Science Inc trades at 12,450 KRW, about 82% below its 52-week high of 70,800 KRW and 1% above the low of 12,380 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 37,195 KRW is for.
Which stocks are comparable to Kolon Life Science Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kolon Life Science Inc stock attractive at the current price?
The data as of Nov 6, 2026: price 12,450 KRW, calculated fair value 37,195 KRW (+199%), Quality Score 35/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 102940 calculated?
We run Kolon Life Science Inc through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 37,195 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Kolon Life Science Inc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kolon Life Science Inc (102940)?
The closing price on Nov 9, 2026 was 12,450 KRW. Our model-based fair value is 37,195 KRW, about +199% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kolon Life Science Inc right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (26,432 KRW). The market is more pessimistic than our downside scenario.

Key figures of Kolon Life Science Inc

How large is the market capitalisation of Kolon Life Science Inc (102940)?
The market capitalisation of Kolon Life Science Inc is 169B KRW (≈ $125M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kolon Life Science Inc (102940)?
The price-to-sales ratio of Kolon Life Science Inc is 0.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Kolon Life Science Inc (102940)?
The net margin of Kolon Life Science Inc is −3.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kolon Life Science Inc (102940)?
The return on equity (ROE) of Kolon Life Science Inc is −3,386% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kolon Life Science Inc (102940)?
On an EBIT basis the return on assets of Kolon Life Science Inc is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kolon Life Science Inc (102940)?
The operating margin of Kolon Life Science Inc is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kolon Life Science Inc (102940)?
Revenue at Kolon Life Science Inc is growing +20.2% versus a year earlier (3y avg +9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kolon Life Science Inc (102940)?
Earnings per share at Kolon Life Science Inc are growing −45.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kolon Life Science Inc (102940) generate?
The free cash flow of Kolon Life Science Inc is −28.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kolon Life Science Inc (102940) carry?
The net debt of Kolon Life Science Inc is 91.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Kolon Life Science Inc in the live analysis

One click puts Kolon Life Science Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.